In the last trading session, 1.61 million BioXcel Therapeutics Inc (NASDAQ:BTAI) shares changed hands as the company’s beta touched 0.84. With the company’s per share price at $4.13 changed hands at -$0.12 or -2.82% during last session, the market valuation stood at $120.89M. BTAI’s last price was a discount, traded about -726.15% off its 52-week high of $34.12. The share price had its 52-week low at $2.23, which suggests the last value was 46.0% up since then. When we look at BioXcel Therapeutics Inc’s average trading volume, we note the 10-day average is 3.58 million shares, with the 3-month average coming to 3.13 million.
Analysts gave the BioXcel Therapeutics Inc (BTAI) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 1.86. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended BTAI as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. BioXcel Therapeutics Inc’s EPS for the current quarter is expected to be -$0.94.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
Instantly BTAI was in red as seen at the end of in last trading. With action -20.12%, the performance over the past five days has been red. The drop to weekly highs of 5.62 on Friday, 11/17/23 subtracted -2.82% to the stock’s daily price. The company’s shares are showing year-to-date downside of -80.77%, with the 5-day performance at -20.12% in the red. However, in the 30-day time frame, BioXcel Therapeutics Inc (NASDAQ:BTAI) is 59.46% up. Looking at the short shares, we see there were 5.81 million shares sold at short interest cover period of 1 days.
The consensus price target for the stock as assigned by Wall Street analysts is $10.50, meaning bulls need an upside of 60.67% from its current market value. According to analyst projections, BTAI’s forecast low is $4.00 with $18.00 as the target high. To hit the forecast high, the stock’s price needs a -335.84% plunge from its current level, while the stock would need to tank 3.15% for it to hit the projected low.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
Data shows that the BioXcel Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -83.62% over the past 6 months, a -1.01% in annual growth rate that is considerably lower than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for BioXcel Therapeutics Inc will rise 51.80%, while the growth in revenue is estimated to hit 44.60% for the next quarter. Year-over-year growth is forecast to reach 377.30% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of $700k. 1 analysts are of the opinion that BioXcel Therapeutics Inc’s revenue for the quarter ending Mar 2024 will be $600k. The company’s revenue for the corresponding quarters a year ago was $238k and $206k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 194.10%. The estimates for the next quarter sales put growth at 191.30%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -84.64%. The 2023 estimates are for BioXcel Therapeutics Inc earnings to increase by 3.61%.
BioXcel Therapeutics Inc is expected to release its next quarterly earnings report on November 14.